In Brief: Canadian Tagamet HB
This article was originally published in The Tan Sheet
Executive Summary
Canadian Tagamet HB: SmithKline Beecham will not launch the H2 antagonist in 100 mg strength in Canada because of the competitive disadvantage caused by delays in the switch process, the company says. SB has received "technical" approval of either one- or two-tablet dosing of the 100 mg form but has not gone through the subsequent descheduling process, requiring a comment period following publication in the Canada Gazette. After descheduling, Tagamet would have been one year behind the launch of Pepcid AC -- the only OTC H2 antagonist in Canada. In the U.S., SmithKline recently replaced the 100 mg form of Tagamet HB with a 200 mg version ("The Tan Sheet" Nov. 18, 1996, p. 1)..
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: